MyChesCo on MSN1mon
Windtree Therapeutics Begins SEISMiC C Trial for Advanced Cardiogenic ShockSCAI Stage C cardiogenic shock is characterized by significant organ hypoperfusion, necessitating the use of inotropic or ...
Zacks Small Cap Research on MSN2mon
WINT: Lead Drug Candidates, Multiple Programs, Several Upcoming Expected MilestonesTo position istaroxime for Phase 3 readiness, WINT is also launching a small Phase 2 study in SCAI Stage C, administering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback